French brain tumor database: 5-year histological results on 25 756 cases, Brain Pathol, vol.21, issue.6, pp.633-677, 2011. ,
Epidemiology for primary brain tumors: a nationwide population-based study, J Neurooncol, vol.131, issue.3, pp.525-571, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01798680
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, vol.131, issue.6, pp.803-823, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Molecular markers in glioma, J Neurooncol. sept, vol.134, issue.3, pp.505-517, 2017. ,
Genetic and molecular epidemiology of adult diffuse glioma, Nat Rev Neurol, vol.15, issue.7, pp.405-422, 2019. ,
Applications of molecular neuro-oncology -a review of diffuse glioma integrated diagnosis and emerging molecular entities, Diagn Pathol. 9 avr, vol.14, issue.1, p.29, 2019. ,
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N Engl J Med. 25 juin, vol.372, issue.26, pp.2499-508, 2015. ,
Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors, Pathologe. juin, vol.40, issue.1, pp.9-17, 2019. ,
Diffuse Infiltrating Oligodendroglioma and Astrocytoma, J Clin Oncol. 20 juill, vol.35, issue.21, pp.2394-401, 2017. ,
WHO classification of tumours of the central nervous system, vol.408, 2016. ,
Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification, Acta Neuropathol. déc, vol.134, issue.6, pp.957-966, 2017. ,
Adult IDH wild-type lower-grade gliomas should be further stratified, Neuro-Oncology, vol.19, issue.10, pp.1327-1364, 2017. ,
Combination genetic signature stratifies lower-grade gliomas better than histological grade, Oncotarget. 28 août, vol.6, issue.25, pp.20885-901, 2015. ,
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities, Acta Neuropathol. sept, vol.130, issue.3, pp.407-424, 2015. ,
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma, Acta Neuropathol. nov, vol.136, issue.5, pp.793-803, 2018. ,
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics, Neuro-Oncology. mai, vol.19, issue.5, pp.614-638, 2017. ,
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas, Neuro-oncology, vol.10, issue.1, pp.66-77, 2018. ,
Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas, N Engl J Med. 25 juin, vol.372, issue.26, pp.2481-98, 2015. ,
cIMPACT-NOW update 3: recommended diagnostic criteria for « Diffuse astrocytic glioma, IDHwildtype, with molecular features of glioblastoma, WHO grade IV », Acta Neuropathol, vol.136, issue.5, pp.805-815, 2018. ,
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria, Neurooncology, 2019. ,
Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling, Mol Cancer. 26 sept, vol.5, p.39, 2006. ,
Microarray-based comparative genomic hybridization (array-CGH) as a useful tool for identifying genes involved in Glioblastoma (GB), Methods Mol Biol, vol.653, pp.35-45, 2010. ,
What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW, J Neuropathol Exp Neurol. 1 avr, vol.78, issue.4, pp.294-300, 2019. ,
cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates, Brain Pathol, vol.29, issue.4, pp.469-72, 2019. ,
cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC), Acta Neuropathol, vol.135, issue.3, pp.481-485, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01735097
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, p.3 ,
URL : https://hal.archives-ouvertes.fr/hal-01771458
, K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant, Acta Neuropathol, vol.135, issue.4, pp.639-681, 2018.
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation, Acta Neuropathol, vol.137, issue.4, pp.683-690, 2019. ,
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDHmutant astrocytomas, Acta Neuropathol. mars, vol.139, issue.3, pp.603-611, 2020. ,
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading, Brain Pathol, vol.19, issue.2020 ,
Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas, Brain Pathol, vol.26, issue.2020 ,
Genetic secrets of long-term glioblastoma survivors, Bosn J Basic Med Sci. 20 mai, vol.19, issue.2, pp.116-140, 2019. ,
Glioma Subclassifications and Their Clinical Significance, Neurotherapeutics, vol.14, issue.2, pp.284-97, 2017. ,
Current therapeutic approaches to diffuse grade II and III gliomas, Ther Adv Neurol Disord, vol.11, p.1756285617752039, 2018. ,
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol, vol.18, issue.6, pp.315-344, 2017. ,
On high-risk, low-grade glioma: What distinguishes high from low? Cancer, vol.15, pp.174-180, 2019. ,
How we treat glioblastoma, ESMO Open, vol.4, issue.2, p.520, 2019. ,
Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma, Sci Rep. 7 févr, vol.10, issue.1, p.2086, 2020. ,
Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system, J Neurooncol. janv, vol.141, issue.1, pp.223-256, 2019. ,
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis, Cancer Cell, vol.15, issue.4, pp.692-704, 2019. ,
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations, Acta Neuropathol, vol.136, issue.2, pp.273-91, 2018. ,
IDH1 and IDH2 Mutations in Gliomas, N Engl J Med, vol.360, issue.8, pp.765-73, 2009. ,
DNA methylation-based classification of central nervous system tumours, Nature, vol.22, issue.7697, pp.469-74, 2018. ,
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development, Acta Neuropathol Commun, vol.25, issue.1, p.59, 2019. ,
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis, Journal of Neuropathology & Experimental Neurology. 1 juin, vol.77, issue.6, pp.422-427, 2018. ,
, Classification OMS 2016 des gliomes infiltrants, vol.1
, 072) RÉSUMÉ Introduction : Les astrocytomes IDH non mutés présentant les caractéristiques moléculaires des glioblastomes (glioblastomes moléculaires, GM) sont un nouveau sous-groupe de gliomes décrit en 2018 par le cIMPACT NOW. Il s'agit d'astrocytomes IDHwt de grade II ou III (AII/III IDHwt) comportant une amplification d'EGFR et/ou un gain du chromosome 7 associé à une perte du chromosome 10 et/ou une mutation de TERT, leur conférant un pronostic similaire aux glioblastomes IDHwt. L'objectif de ce travail est d, Courbes de survie (Kaplan Meier) des glioblastomes IDHwt (n = 23) en fonction du traitement par STUPP, vol.2, p.0
, Une analyse statistique a été réalisée afin de comparer la survie des GM et celle des AII/III IDHwt sans critère moléculaire de glioblastome, Matériel et Méthodes : L'ensemble des AII/III IDHwt ayant eu une CGH array entre le 1 er janvier 2016 et le 31 aout 2019 au CHU de Lille ont été inclus
, Le principal facteur impliqué dans la survie des GM était le statut de méthylation du promoteur de MGMT (HR 0,948, GM et 13 AII/III IDHwt ont été inclus, vol.420, p.0
, Après appariement des GM avec des glioblastomes IDHwt, la survie médiane entre ces deux groupes était similaire (14,36 mois vs 13,44 mois, vol.269, p.0
, Conclusion : Notre étude confirme que la survie des GM est similaire à celle des glioblastomes IDHwt. Elle est également comparable à celle des autres AII/III IDHwt. D'autres marqueurs moléculaires semblent nécessaires à rechercher afin d